HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of Fluvastatin on Cardiovascular Complications in Kidney Transplant Patients: A Systemic Review and Meta-analysis.

AbstractBACKGROUND:
Hyperlipidemia and cardiovascular disease are risk factors for long-term renal transplant dysfunction. However, no meta-analyses of randomized controlled trials have investigated the effects of statin treatment on graft function in renal transplant recipients. The aim of the present study was to evaluate the effects of statin use on renal transplant patients using a meta-analysis approach.
METHODS:
We conducted a systematic review and meta-analysis using random effects modeling. We searched the following databases for all studies published through to June 15, 2018: Cochrane Central Register, OVID MEDLINE, Embase, and PubMed. We reviewed all relevant reviews, registered trials, and relevant conference proceedings to compare clinical outcomes and survival between fluvastatin recipients and controls.
RESULTS:
Five trials with a total of 3725 patients were included. Glomerular filtration rates, graft loss, tacrolimus level, antibody-mediated rejection, T cell-mediated rejection, proteinuria, fungal infection (candida), and patient survival rates did not differ between the fluvastatin and control groups. However, major adverse cardiovascular events were 1.547 times more common in the control group than in the fluvastatin group (P = .001).
CONCLUSIONS:
Fluvastatin use was associated with a reduction in major adverse cardiac events among kidney transplant patients.
AuthorsSeun Deuk Hwang, Jin Ho Lee, Jong Hyun Jhee, Yoon Ji Kim, Keun-Myoung Park, Joong Kyung Kim, Seoung Woo Lee, Joon Ho Song
JournalTransplantation proceedings (Transplant Proc) Vol. 51 Issue 8 Pg. 2710-2713 (Oct 2019) ISSN: 1873-2623 [Electronic] United States
PMID31447193 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
CopyrightCopyright © 2019 Elsevier Inc. All rights reserved.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Fluvastatin
Topics
  • Cardiovascular Diseases (complications, drug therapy)
  • Fluvastatin (therapeutic use)
  • Graft Rejection (epidemiology)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Kidney Transplantation (mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: